ZNF658 Inhibitors
Zinc finger protein 658 (ZNF658) inhibitors encompass a variety of chemicals that target different pathways to achieve inhibition of this transcription factor. Specific inhibitors of the MAPK/ERK pathway, by altering the phosphorylation states of proteins that interact with ZNF658 or its target genes, can impact the DNA-binding activity of ZNF658, thereby inhibiting its function. The PI3K/AKT signaling pathway, which can regulate transcription factors post-translationally, may also be manipulated to alter ZNF658's activity through nuclear signaling and transcriptional regulation. Furthermore, inhibitors that target components of the stress response pathways, such as p38 MAPK, could indirectly modify ZNF658's activity by disrupting its regulatory mechanisms. The mTOR signaling pathway, which orchestrates protein synthesis, is another target for indirect inhibition; disruptions here could reduce ZNF658's functional activity if it is subject to mTOR-dependent regulatory controls.
Additionally, proteasome inhibitors may prevent the degradation of regulatory proteins that influence ZNF658's transcriptional responses, leading to an indirect inhibition of its function. Epigenetic modulators, such as histone deacetylase inhibitors and DNA methyltransferase inhibitors, could affect ZNF658by modifying the chromatin structure and DNA methylation patterns, respectively, which in turn influences ZNF658's ability to bind DNA and regulate gene expression. Cell cycle progression, which can be altered by cyclin-dependent kinase inhibitors, may also play a role in modulating the activity of ZNF658 if its function is linked to cell cycle events. Furthermore, the disruption of calcium signaling by antagonizing calmodulin or inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA) could lead to an indirect inhibition of ZNF658, assuming its activity is calcium-dependent.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound is a specific MEK inhibitor, which disrupts the MAPK/ERK pathway. ZNF658, being a transcription factor, could have its DNA-binding activity altered due to changes in phosphorylation states of proteins that interact with ZNF658 or its target genes as a consequence of MAPK pathway modulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that impedes the PI3K/AKT signaling pathway. Since PI3K/AKT can regulate transcription factors through post-translational modifications, ZNF658's activity might be indirectly inhibited due to altered nuclear signaling and transcriptional regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
An inhibitor of p38 MAPK, used to block p38-mediated signaling pathways. If ZNF658 is regulated through stress response pathways that involve p38 MAPK, its activity would be indirectly inhibited via this chemical. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
By inhibiting mTOR, this compound disrupts downstream protein synthesis signaling, potentially reducing the functional activity of ZNF658 if it is regulated by mTOR-dependent pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that can prevent the degradation of regulatory proteins that control the activity of transcription factors like ZNF658, potentially leading to altered transcriptional responses. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
This histone deacetylase inhibitor changes the chromatin state and may affect the binding of ZNF658 to DNA by altering the acetylation status of histones and other proteins, thereby affecting its transcription regulatory functions. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A DNA methyltransferase inhibitor that changes the methylation status of DNA. It could indirectly affect the binding affinity of ZNF658 to its target DNA sequences by altering the epigenetic landscape of the genome. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
An MEK inhibitor that impedes the MAPK/ERK signaling pathway. By doing so, it could alter the activity of ZNF658 indirectly, as the transcription factor might be regulated by signaling cascades that involve MEK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
This compound is an inhibitor of JNK, part of the MAPK signaling cascade. Inhibition of JNK could affect ZNF658's activity if it is involved in cellular responses to stress that rely on JNK signaling. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
A calmodulin antagonist that disrupts calcium signal transduction pathways. As calcium signaling can influence transcription factor activity, ZNF658's function may be indirectly inhibited by alterations in calcium-dependent signaling. | ||||||